展商
展品
瑞普佳®
展商：Takeda Pharmaceutical Company Limited
原产国/地区：日本
国内首个由人类细胞系通过基因工程技术制得的人类蛋白质α-半乳糖苷酶A。适用于6岁以上的儿童、青少年和成人法布雷病患者的长期酶替代治疗。瑞普佳®已于2022年1月正式进入国家医保目录，惠及帮助更多中国法布雷病患者及家庭
展品详情
Replagal® (agalsidase alfa) was listed in the 2nd batch of urgent medical needs issued by the health authority in March 2018. Through accelerated approval, this NDA approval enabled this innovative medicine quickly benefit the patients in China. Now Replagal® has successfully entered NRDL in January 2022.